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Summary
Objective: This study evaluated antibiotic resistance trends in Streptococcus pneu-
moniae isolated in a tertiary hospital in Kuwait and its implications for empiric
therapy.
Materials and methods: Antimicrobial susceptibility of 1353 strains of S. pneumoniae
isolated from clinical specimens during 1997—2007 was performed by disc diffusion
method. MIC was determined by E test. The results were compared for 1997—2001,
2002—2005 and 2006—2007.
Results: The prevalence of resistance for the respective periods were as follows:
penicillin, 51.3%, 61.3% and 54.5%; erythromycin, 31.2%, 36.7% and 37.7%; tetracy-
cline, 30.8%, 45.3% and 41.3%; co-trimoxazole, 49.5%, 58.5% and 62.8%; clindamycin,
20.4%, 20.6% and 24.5% and chloramphenicol, 8.1%, 8.9% and 3.7%. All were sus-
ceptible to vancomycin and rifampicin. For oxacillin-resistant isolates, penicillin
resistance was rare (0.8%) with the new non-meningeal breakpoint. However, using
the meningeal breakpoints, resistance increased for penicillin from 0.6%, to 28.7%,
for cefotaxime from none to 16.5%, and for ceftriaxone from none to 7%. Intermedi-
ate resistance to meropenem increased from 1.7% to 22.4%. Multiple drug resistance
increased from 22.4% to 37.8%.
∗ Corresponding author. Tel.: +965 2 4986773; fax: +965 2 5332719.
E-mail address: EDET@hsc.edu.kw (E.E. Udo).
876-0341/$ — see front matter © 2010 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.
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Conclusion: The study demonstrated that antimicrobial resistance of S. pneumoniae
is increasing in Kuwait. However, the results of MIC determinations indicated that
penicillin can still be used for therapy of non-meningeal infections. High prevalence
of erythromycin resistance suggests that therapy of pneumonia with a macrolide alone
may result in failure and should be based on results of susceptibility testing.
dulaziz University for Health Sciences. Published by Elsevier
I
S
m
b
[
n
a
i
o
e
o
c
i
t
r
t
p
t
a
c
v
l
m
b
l
m
r
o
t
1
M
B
C
l
M
i
D
A
I
K
S
C
d
u
i
b
−
A
S
p
b
d
s
d
t
r
a
c
t
d
a
i
c
i
p
d
B
m
w
o
[
l
a
n
R
0
Analysis of results© 2010 King Saud Bin Ab
Ltd. All rights reserved.
ntroduction
treptococcus pneumoniae continues to be a com-
on cause of serious infections such as pneumonia,
acteremia, meningitis, otitis media and sinusitis
1]. In recent years, resistance of S. pneumo-
iae to penicillin and other -lactams as well
s non--lactam antibiotics has been increasing
n many countries [2—4]. This limits therapeutic
ptions available for the treatment of life threat-
ning pneumococcal infections. The upward trend
f resistance is likely to continue because of the
ontinuing antibiotic pressure [2,5]. The clinical
mpact of pneumococcal resistance varies with
he site of infection and the ability of immune
esponse to clear the infection [6]. Since the mor-
ality rate of invasive infections caused by resistant
neumococci is high [1], rapid and accurate detec-
ion of resistance may improve the selection of
ppropriate antibiotics and better treatment out-
omes.
The incidence of penicillin resistance is quite
ariable geographically and may reﬂect the local
evel of antibiotic usage [3—5]. Since most pneu-
ococcal infections are treated on an empirical
asis, knowledge of the susceptibility patterns of
ocal isolates is important for proper manage-
ent of these infections. This paper presents the
esults of a laboratory-based surveillance of antibi-
tic resistance in S. pneumoniae obtained in a
ertiary hospital in Kuwait, during the period of
997—2007.
aterials and methods
acterial isolates
onsecutive single isolates of S. pneumoniae iso-
ated from clinical specimens received in the
icrobiology laboratory of the Al-Amiri Hospital
n Kuwait during the period of January 1997 to
ecember 2007 were included in this study. The
l-Amiri hospital is a 500 bed tertiary hospital.
t is one of the teaching hospitals afﬁliated with
uwait University Medical School. It has Medical,
T
n
2urgical, Pediatrics, Nephrology, Gastroenterology,
ardiology, Intensive Care as well as Outpatient
epartments.
S. pneumoniae was isolated and identiﬁed
sing traditional bacteriological methods includ-
ng colony morphology, optochin susceptibility and
ile solubility test. The isolates were preserved at
80 ◦C in 10% (w/v) skimmed milk.
ntimicrobial susceptibility tests
. pneumoniae was screened for susceptibility to
enicillin with a 1g oxacillin disc (BBL Micro-
iology Systems, Cockeysville, MD) by the disc
iffusion method according to the performance
tandards from CLSI [7]. Isolates with a zone
iameter ≥20mm were considered susceptible (S)
o penicillin and ≤19mm, either intermediate
esistant (I) or resistant (R). Other antimicrobial
gents tested by disc diffusion were erythromycin,
lindamycin, tetracycline, chloramphenicol, co-
rimoxazole, vancomycin and rifampicin. Zone
iameter interpretive standards were deﬁned
ccording to the CLSI guideline [7]. Minimum
nhibitory concentrations (MICs) for penicillin G,
efotaxime, ceftriaxone, cefuroxime, meropenem,
mipenem, erythromycin, clindamycin, chloram-
henicol, vancomycin and ciproﬂoxacin were
etermined with E test strips (PDM Epsilometer, AB
iodisk, Solna, Sweden) according to the recom-
endations of the manufacturer. Quality control
as carried out according to the recommendation
f CLSI using S. pneumoniae strain ATCC 49619
7] and a known penicillin susceptible local iso-
ate as the control strains. The MIC was interpreted
ccording to the CLSI breakpoints [7]. For penicillin
on-meningeal, MIC ≤2mg/l S, 4mg/l I, ≥8mg/l
and meningeal breakpoints, MIC ≤0.06mg/l S,
.1—1mg/l I, ≥2mg/l R were used [8].he results of disc diffusion tests and MIC determi-
ations were analyzed in three periods; 1997—2001,
002—2005 and 2006—2007.
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tFigure 1 Resistance rates of S. pneumoniae isolates by
tetracycline; Cm, chloramphenicol; CL, clindamycin; SXT
Results
In total, 1353 S. pneumoniae isolates consisting
of 472 obtained in 1997—2001, 532 in 2002—2005
and 349 obtained in 2006—2007. They were iso-
lated from respiratory tract (994, 73.5%), blood
(121, 8.9%), CSF (15, 1.1%), ear (97, 7.2%) and eye
(126, 9.3%) samples. The age of the patients ranged
between 1 month and 85 years. Four hundred and
sixty (34.0%) of them were 12 years old or younger
while 893 (66.0%) of them were older.
The results of the disc diffusion test are
summarized in Fig. 1. In total, 758 isolates
(56.0%) were resistant to oxacillin during the
surveillance period. The prevalence of oxacillin
resistance increased from 51.3% in 1999—2001
to 61.3% in 2002—2005 and then declined to
54.4% in 2006—2007. Similarly, the prevalence of
tetracycline resistance increased from 30.8% in
1999—2001 to 45.3% in 2002—2005 and declined
to 41.3% in 2006—2007. The prevalence of ery-
thromycin resistance increased slightly from 31.2%
in 1999—2001 to 36.7% and 37.7% in 2002—2005 and
2006—2007 respectively whereas the prevalence of
co-trimoxazole resistance increased steadily from
49.5% in 1999—2001 to 58.5% in 2002—2005 and
62.8% in 2006—2007. Chloramphenicol resistance
declined from 8.1% in 1999—2001 and 8.9% in
2002—2005 to 3.7% in 2006—2007. There was no sig-
niﬁcant change in the prevalence of clindamycin
resistance which was detected in 20.4%, 20.6% and
24.5% respectively during the three periods of the
study. All of the isolates were susceptible to van-
comycin and rifampicin.
l
a
o
cdiffusion method. OX, oxacillin; Em, erythromycin; Tet,
trimoxazole.
Results of MIC determination conﬁrmed the
esults of disc diffusion method. The oxacillin-
usceptible isolates were also susceptible to
enicillin G and other -lactam antibiotics. Table 1
hows the susceptibility of the oxacillin-resistant S.
neumoniae isolates to -lactam antibiotics based
n MIC determination. Based on the meningeal
reakpoints, 9.5%, 4.5% and none of the oxacillin-
esistant isolates were susceptible to penicillin G,
hereas the majority expressed intermediate resis-
ance (89.9%, 89.8% and 71.3%), and 0.6%, 5.7%
nd 28.7% were resistant during the three peri-
ds of study respectively. However, according to
he new non-meningeal breakpoint [8], all isolates
ere susceptible to penicillin (MIC ≤2mg/l) dur-
ng the ﬁrst and second periods and 0.8% of the
solates during the third period expressed interme-
iate resistance.
The MIC of penicillin, ampicillin and
moxicillin—clavulanate showed essentially equiv-
lent results when compared (not shown). The
IC of all -lactam agents increased as penicillin
ICs increased throughout the study period. This
as true for cefuroxime, cefotaxime, ceftriaxone,
eropenem and imipenem. For blood and CSF iso-
ates, MIC studies for penicillin showed increase in
ully resistant isolates (by meningeal breakpoints),
0.7% were resistant during 2006—2007 compared
o 2.2% that were resistant during 2002—2005.
When the prevalence of oxacillin-resistant iso-ates of S. pneumoniae was assessed according to
ge groups, children (≤12 years) showed higher rate
f oxacillin-resistant isolates compared to adoles-
ents and adults during all the three study periods.
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Table 1 Resistance rates (%) of -lactam agents by E test for OX-R isolates of S. pneumoniae.
Antimicrobial agent MIC breakpoints (mg/l) 1997—2001
(178 OX-R)
2002—2005
(247 OX-R)
2006—2007
(122 OX-R)
I (%) R (%) I (%) R (%) I (%) R (%)
Penicillin G
Meningeal ≤0.06 S, 0.1—1 I, ≥2 R 89.9 0.6 89.8 5.7 71.3 28.7
Non-meningeal ≤2 S, 4 I, ≥8 R 0 0 0 0 0.8 0
Cefotaxime
Meningeal ≤0.5 S, 1 I, ≥2 R 9.6 0 16.8 5.3 30.7 16.5
Non-meningeal ≤1 S, 2 I, ≥4 R 0 0 4.9 0.4 16.5 0
Ceftriaxone
Meningeal ≤0.5 S, 1 I, ≥2 R 13.5 0 17 1.8 45.3 7
Non-meningeal ≤1 S, 2 I, ≥4 R 0 0 1.8 0 7 0
Cefuroxime sodium ≤0.5 S, 1 I, ≥2 R 14 30 19.3 32.1 13.1 56.5
Meropenem ≤0.25 S, 0.5 I, ≥1 R — — 1.7 0 22.4 0.8
Imipenem ≤0.12 S, 0.25—0.5 I, ≥1 R — — 4.1 0 34.6 0
MIC range, mg/l; penicillin 0.06—2, 0.06—2, 0.12—4; cefotaxime 0.03—1, 0.03—4, 0.03—2; ceftriaxone 0.03—1, 0.03—2, 0.06—2;
cefuroxime sodium 0.03—4, 0.03—16, 0.06—8 for the three periods respectively; meropenem 0.01—0.5, 0.03—1; imipenem
ly.
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Table 2 shows the resistance rates of non--
actam antibiotics in the oxacillin-resistant (OX-R)
solates. The result shows that 18.3%, 14.3%
nd 12.5% of OX-R isolates were resistant to
hloramphenicol during the three periods respec-
ively. More than 50% of them were resistant
o erythromycin and 26.2% and 35.3% of OX-
isolates were resistant to clindamycin during
he latter two periods respectively (Table 2). All
lindamycin-resistant isolates were also resistant
o erythromycin and isolates with erythromycin MIC
64mg/l were resistant to clindamycin. However,
solates with erythromycin MIC 1—32mg/l were sus-
eptible to clindamycin. Ciproﬂoxacin resistance
as detected in the OX-R isolates only during
002—2005.
e
t
m
Table 2 Resistance rates of non--lactam agents by E test
Antimicrobial agent MIC breakpoints mg/l 1997—20
(178 OX-
Erythromycin ≤0.25 S, ≥1 R ND
Clindamycin ≤0.25 S, ≥1 R ND
Chloramphenicol ≤4 S, ≥8 R 18.3
Vancomycin ≤1 S 0
Ciproﬂoxacin ≥4 Ra ND
MIC range, erythromycin 0.03 to ≥256, 0.03 to ≥256mg/l; clindamy
respectively); clindamycin R isolates had erythromycin MIC ≥64mg
MIC range, chloramphenicol 0.25—32, 0.5—32, 1—32mg/l; vancomyc
tively); ciproﬂoxacin MIC range 0.25—16, 0.25—1 (for the latter two
ND: not done.
a Ciproﬂoxacin MIC ≥4mg/l indicates resistance to new ﬂuoroquultiple drug resistance
hen patterns of multiple drug resistance (resis-
ance to three or more classes of antibiotics) were
nalyzed, during 1997—2001 and 2002—2005, co-
esistance to penicillin (OX-R) plus resistance to
t least two of the following drugs, erythromycin,
etracycline, chloramphenicol and co-trimoxazole
as found in 22.4% and 37.8% of all isolates
espectively. Multiple drug resistance was seen in
0% and 11.4% of the penicillin susceptible iso-
ates and in 43.4% and 57.4% of the OX-R isolates
espectively. Co-resistance to penicillin (OX-R) with
rythromycin, tetracycline, clindamycin and co-
rimoxazole was the most common pattern of
ultiple drug resistance.
for OX-R isolates of S. pneumoniae.
01
R), R (%)
2002—2005
(247 OX-R), R (%)
2006—2007
(122 OX-R), R (%)
52.9 51
26.2 35.3
14.3 12.5
0 0
2.4 0
cin 0.03 to ≥256, 0.06 to ≥256mg/l (for the latter two periods
/l, high level R.
in 0.12—1, 0.25—1, 0.25—1mg/l (for the three periods respec-
periods respectively).
inolones [9].
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Discussion
This study provided an opportunity to observe
changes in the prevalence of antibiotic resistance in
clinical isolates of S. pneumoniae in a tertiary hos-
pital in Kuwait during the past decade. The results
demonstrated that the rate of antimicrobial resis-
tance in S. pneumoniae isolated in this hospital
was increasing for the commonly used antibiotics.
Except for a reduction in penicillin resistance
during 2006—2007 (Fig. 1), the results for MIC
determinations for OX-R isolates (Table 1), showed
increases in isolates that were fully resistant to
penicillin (0.6%, 5.7% and 28.7%) by meningeal
breakpoints [8] throughout the study period and
when compared to previous reports [9—12]. The
increasing prevalence of penicillin resistance in S.
pneumoniae obtained in this study is consistent
with recent reports of penicillin resistance in other
countries in the region such as Saudi Arabia [3,13]
and Egypt [14].
The present level of penicillin resistance of S.
pneumoniae isolates in Kuwait has implications
for therapy of pneumococcal meningitis, due to
low concentrations of the antibiotic in CSF [9].
Evidence has been increasing for years that peni-
cillin is effective against pneumococcal pneumonia
at concentrations that would fail for meningitis
[15]. According to the new FDA approved and
CLSI adopted non-meningeal breakpoints for peni-
cillin [8], penicillin resistance is rare among our
isolates and most cases of non-meningeal pneumo-
coccal infections are likely to respond to penicillin
therapy. In this study, penicillin, ampicillin and
amoxicillin/clavulanate had essentially equivalent
MIC values for the isolates. Hence, high doses of oral
amoxicillin (MIC ≤2mg/l) may be effective against
most of the isolates [16].
We observed that the MIC of other -lactam
agents increased as penicillin MIC increased
(Table 1) as has also been reported by others
[9], probably because these antibiotics bind to
the same penicillin binding proteinsAlthough a
previous study provided evidence suggesting that
intravenous cefuroxime 1.5 g eight hourly was an
effective therapy for bacteremic pneumococcal
pneumonia due to cefuroxime-resistant isolates
with MICs up to 4mg/l [17], other studies have
reported treatment failures with cefuroxime [18].
Therefore, considering the high prevalence of
cefuroxime resistance observed in this study, intra-
venous and oral cefuroxime as well as other broad
spectrum cephalosporins should be used with cau-
tion. The increase in resistance to cefotaxime,
ceftriaxone andmeropenem is of particular concern
for empiric therapy of pneumococcal meningitis as
o
m
r
aM. Johny et al.
t further limits the choice of antibiotics available
or the therapy of pneumococcal meningitis [19].
Although all strains were susceptible to van-
omycin, it is not recommended for monotherapy
n meningitis because of its variable CSF levels
ue to difﬁculty in crossing the blood brain bar-
ier [19]. Although chloramphenicol resistance was
ow among our isolates, it is rarely used nowadays
ecause of the risk of aplastic anemia. In addition,
herapeutic failure with chloramphenicol in pneu-
ococcal meningitis has been reported [20].
As observed in other studies [9], clindamycin
esistance indicated high level resistance to ery-
hromycin, since all clindamycin resistant isolates
ad erythromycin MIC ≥64mg/l.
The in vitro/in vivo paradox with macrolide
roup of antibiotics, referring to discordance
etween reported in vitro resistance and clinical
uccess, has been documented in respiratory infec-
ions. Macrolides are commonly prescribed for the
anagement of community-acquired pneumonia in
utpatients, with the newer generation macrolides
clarithromycin and azithromycin) often used as
onotherapy [21]. However, the high prevalence
f erythromycin resistance (37.7%) in S. pneumo-
iae with predominance of highly resistant strains
MIC ≥64mg/l) observed in this study is of con-
ern for empiric therapy of community-acquired
neumonia because therapeutic failure with these
gents has been reported [18], and many clinicians
aution against using these agents as monotherapy
n areas with high prevalence of resistance [21].
herefore, based on the results of this study, the
se of macrolides alone in pneumococcal diseases
ay result in clinical failure of therapy [22].
The high prevalence of tetracycline and co-
rimoxazole resistance (41.3%% and 62.8% respec-
ively) reported in this study adds further problems
o the management of pneumococcal diseases.
The emergence of penicillin resistance in S.
neumoniae resulted in the increased use of newer
uoroquinolones for empiric therapy of community-
cquired pneumonia [15]. This also resulted in
he emergence of strains that were resistant to
uoroquinolones arousing concern with regard to
reatment of pneumococcal disease. The spread of
uoroquinolone-resistant clones may cause rapid
ncrease in resistance with widespread use of these
gents as has been reported from Canada and
ong Kong [3,5]. A weakness of this study is that
iproﬂoxacin resistance was tested only in the
xacillin-resistant isolates and the results reported
ay not reﬂect the true prevalence of ciproﬂoxacin
esistance in our pneumococcal population.
Multi drug resistant pneumococci have become
serious clinical problem in recent years which
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[neumococcal resistance in a Kuwait hospital
s conﬁrmed by the results that more than one
hird (37.8%) of isolates in this study were resistant
o multiple antibiotics. The increase in resistance
ccurred mostly among penicillin non-susceptible
solates as observed by others [9,22]. Since antibi-
tics are available only by prescription with no
ver the counter sales in Kuwait, antibiotic misuse
nd failure to follow antibiotic policy guidelines in
he private sector may contribute to the increas-
ng resistance observed in this study. Alternatively,
mportation of resistant clones into Kuwait by
xpatriate workers from countries with high preva-
ence of antibiotic-resistant pneumococci [9,22]
r returning patients who sought medical care
broad could be a major reason for the increase
n resistance of S. pneumoniae observed in this
tudy.
In conclusion, this surveillance study clearly
ocuments increase in the prevalence of antibi-
tic resistance and multiple drug resistance of S.
neumoniae in Kuwait. Although -lactam resis-
ant strains of S. pneumoniae are increasing in
uwait, the MIC studies indicate that the effect
f the -lactam resistance affects mainly the ther-
py of meningitis and not that of non-meningeal
nfections. This supports the continued use of
-lactam agents such as penicillin G, ampicillin
r amoxicillin in non-meningeal infections. How-
ver, oral broad spectrum cephalosporins should
e used with caution considering the high level
f resistance to cefuroxime detected in this study.
rythromycin resistance is high in Kuwait and ther-
py of pneumonia with a macrolide alone may
esult in failure. In view of increasing macrolide
esistance in S. pneumoniae reported in this study
nd elsewhere [4,9,21], treatment of community-
cquired pneumonia should be based on guidelines
roduced by Gulf Corporation Council CAP Work-
ng Group (GCC-CAPWG) [23]. New ﬂuoroquinolones
hould be used discriminately, since clonal spread
f ﬂuoroquinolone-resistant strains may cause rapid
ncrease in resistance and loss of efﬁcacy of these
gents. Continuous surveillance of antimicrobial
esistance among pneumococcal isolates in local
egions, pneumococcal vaccination and appropri-
te use of antibiotics are essential to control this
roblem.
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